高级搜索

YC-1对人肝细胞癌裸鼠移植瘤的影响及其机制

吴晓慧, 王顺祥, 杨永江, 李建坤

吴晓慧, 王顺祥, 杨永江, 李建坤. YC-1对人肝细胞癌裸鼠移植瘤的影响及其机制[J]. 肿瘤防治研究, 2011, 38(08): 895-898. DOI: 10.3971/j.issn.1000-8578.2011.08.011
引用本文: 吴晓慧, 王顺祥, 杨永江, 李建坤. YC-1对人肝细胞癌裸鼠移植瘤的影响及其机制[J]. 肿瘤防治研究, 2011, 38(08): 895-898. DOI: 10.3971/j.issn.1000-8578.2011.08.011
WU Xiao-hui, WANG Shun-xiang, YANG Yong-jiang, LI Jian-kun. Mechanism of Effects of YC-1 on Human Primary Hepatic Carcinoma Loaded in Nude Mice[J]. Cancer Research on Prevention and Treatment, 2011, 38(08): 895-898. DOI: 10.3971/j.issn.1000-8578.2011.08.011
Citation: WU Xiao-hui, WANG Shun-xiang, YANG Yong-jiang, LI Jian-kun. Mechanism of Effects of YC-1 on Human Primary Hepatic Carcinoma Loaded in Nude Mice[J]. Cancer Research on Prevention and Treatment, 2011, 38(08): 895-898. DOI: 10.3971/j.issn.1000-8578.2011.08.011

YC-1对人肝细胞癌裸鼠移植瘤的影响及其机制

详细信息
  • 中图分类号: R735.7

Mechanism of Effects of YC-1 on Human Primary Hepatic Carcinoma Loaded in Nude Mice

  • 摘要: 目的探讨缺氧诱导因子抑制剂(YC-1)对人肝癌细胞裸鼠皮下移植瘤的影响及其相关机制。方法用人肝癌细胞株SMMC-7721建立人肝癌裸鼠皮下移植瘤模型,待肿瘤生长至约(100~150)mm3时,将荷瘤裸鼠随机分为两组:实验组和对照组,分别给予YC-1和二甲基亚砜,观察两组裸鼠肿瘤生长情况;应用RT-PCR、Western blot及免疫组织化学方法检测移植瘤组织HIF-1α和VEGF表达。结果YC-1治疗组各时点肿瘤体积显著低于对照组(P<0. 05 );与对照组比较,实验组移植瘤组织HIF-1α mRNA表达差异无统计学意义(P>0.05),而HIF-1α蛋白的表达显著降低 (P<0. 05 );移植瘤组织VEGFmRNA及蛋白表达均显著低于对照组 (P<0. 05 )。结论YC-1可能通过下调HIF-1α和VEGF的表达来抑制肝癌的生长。

     

    Abstract: ObjectiveTo research the mechanism of effects of HIF-1α (YC-1) on implanted human primary hepatic carcinoma in nude mice. MethodsA total of 16 male nude mice were inoculated subcutaneously with 1 million SMMC-7721 cells. Once the tumor grew to (100~150)mm3, the mice were divided randomly into two groups and injected with YC-1 or DMSO respectively. Tumor size and weight were measured. Levels of HIF-1α and VEGF expressions in tumor tissue were detected by RT-PCR, Westetn blot or immunohistochemical respectively. ResultsTumors grew rapidly in the control group than those in the YC-1 treatment group. In YC-1 group therapy resulted in low expression of HIF-1α and VEGF than those in control groups(P<0.05). ConclusionYC-1 therapy was a promising approach to treat human liver cancer by suppression of HIF-1α and VEGF expression, which might contribute to inhibit tumor growth and angiogenesis.

     

计量
  • 文章访问数:  2007
  • HTML全文浏览量:  15
  • PDF下载量:  470
  • 被引次数: 0
出版历程
  • 收稿日期:  2010-08-01
  • 修回日期:  2011-01-19
  • 刊出日期:  2011-08-24

目录

    /

    返回文章
    返回
    x 关闭 永久关闭